ICUD-EAU International Consultation on Bladder Cancer 2012: Non–Muscle-Invasive Urothelial Carcinoma of the Bladder

Burger, Maximilian; Oosterlinck, Willem; Konety, Badrinath R.; Chang, Sam S.; Guðjónsson, Sigurður; Pruthi, Raj S.; Soloway, Mark S.; Solsona, E.; Sved, Paul; Babjuk, Marko; Brausi, Maurizio; Cheng, Christopher; Compérat, Éva; Dinney, Colin P.; Otto, Wolfgang; Shah, Jay B.; Thürof, Joachim; Witjes, J. Alfred

doi:10.1016/j.eururo.2012.08.061

Cited by 152 publications

(111 citation statements)

References 48 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…9 Even though each of these guidelines is based on largescale literature reviews on similar avail able data, the guidelines are somewhat disparate, making implementation of the recommendations into routine practice difficult for the practicing urologist.…”

Section: Review Of Current Guidelines On Bcg Usementioning

confidence: 99%

“…In addi tion, the value of maintenance therapy in T1 disease is questioned. 9 Carcinoma in situ (CIS) is the only patho logy for which maintenance is advised by ICUD and the guideline also includes reinduction of BCG instillations if no response is detected at first evaluation. 9 The NCCN recommends BCG as standard treatment for CIS only, but lists BCG as the favoured option for highgrade Ta and T1 tumours and offers that maintenance should be considered.…”

Section: High-grade Tumours (Including Carcinoma In Situ)mentioning

confidence: 99%

See 1 more Smart Citation

Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

| Multiple clinical trials have demonstrated that intravesical Bacillus Calmette-Guérin (BCG) treatment reduces recurrences and progression in patients with non-muscle-invasive bladder cancer (NMIBC). However, although BCG has been in use for almost 40 years, this agent is often underutilized and practice patterns of administration vary. This neglect is most likely caused by uncertainties about the optimal use of BCG, including unawareness of optimal treatment schedules and about patient populations that most benefit from BCG treatment. To address this deficit, a focus group of specialized urologic oncologists (urologists, medical oncologists and radiation oncologists) reviewed the current guidelines and clinical evidence, discussed their experiences and formed a consensus regarding the optimal use of BCG in the management of patients with NIMBC. The experts concluded that continuing therapy with 3-week BCG maintenance is superior to induction treatment only and is the single most important factor in improving outcomes in patients with NMIBC. They also concluded that a reliable alternative to radical cystectomy in truly BCG-refractory disease remains the subject of clinical trials. In addition, definitions for common terms of BCG failure, such as BCG-refractory and BCG-intolerant, have been formulated.

show abstract

Section: Review Of Current Guidelines On Bcg Usementioning

confidence: 99%

Section: High-grade Tumours (Including Carcinoma In Situ)mentioning

confidence: 99%

Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Patients were followed every 3-6 months during the first 2 years after TURB, biannually up to 5 years, and annually thereafter (Babjuk et al, 2011;Burger et al, 2012). Followup consisted of a history, physical examination, urinary cytology, cystoscopy, and biopsy of suspicious lesions.…”

Section: Patientsmentioning

confidence: 99%

1701 Accuracy of the Eortc Risk Tables and of the Cueto Scoring Model to Predict Outcomes in Non Muscle-Invasive Urothelial Carcinoma of the Bladder

et al. 2013

View full text Add to dashboard Cite

Background: The European Organization for Research and Treatment of Cancer (EORTC) risk tables and the Spanish Urological Club for Oncological Treatment (CUETO) scoring model are the two best-established predictive tools to help decision making for patients with non-muscle-invasive bladder cancer (NMIBC). The aim of the current study was to assess the performance of these predictive tools in a large multicentre cohort of NMIBC patients.

show abstract

“…[3][4][5] According to the International Bladder Cancer Group for low-risk NMIBC, there is an absolute risk reduction of recurrence of 17% with instillation of mitomycin C (MMC) into the bladder in the immediate postoperative period. [48] Additional studies have confirmed these results and…”

Section: Other Considerationsmentioning

confidence: 99%

“…[2] The American Urological Association (AUA), European Association of Urology (EAU), and Society of International Urology (SIU) guidelines state that when possible, a complete resection of all bladder tumors should be performed. [3][4][5] Multiple studies have reported between 30%-70% of residual cancer on repeat TUR. [6,7] Even an apparently well-performed TURBT is not always complete, depending on the pathology of the tumor.…”

Section: Introductionmentioning

confidence: 99%

Approaching the optimal transurethral resection of a bladder tumor

Jurewicz

Soloway

2014

Turkish Journal of Urology

View full text Add to dashboard Cite

A complete transurethral resection of a bladder tumor (TURBT) is essential for adequately diagnosing, staging, and treating bladder cancer. A TURBT is deceptively difficult and is a highly underappreciated procedure. An incomplete resection is the major reason for the high incidence of recurrence following initial transurethral resection and thus to the suboptimal care of our patients. Our objective was to review the preoperative, intraoperative, and postoperative considerations for performing an optimal TURBT. The European Association of Urology, Society of International Urology, and The American Urological Association guidelines emphasize a complete resection of all visible tumor during a TURBT. This review will emphasize the various techniques and treatments, including photodynamic cystoscopy, intravesical chemotherapy, and a perioperative checklist, that can be used to help to enable a complete resection and reduce the recurrence rate. A Medline/PubMed search was completed for original and review articles related to transurethral resection and the treatment of non-muscle-invasive bladder cancer. The major findings were analyzed and are presented from large prospective, retrospective, and review studies.

show abstract

ICUD-EAU International Consultation on Bladder Cancer 2012: Non–Muscle-Invasive Urothelial Carcinoma of the Bladder

Cited by 152 publications

References 48 publications

Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

1701 Accuracy of the Eortc Risk Tables and of the Cueto Scoring Model to Predict Outcomes in Non Muscle-Invasive Urothelial Carcinoma of the Bladder

Approaching the optimal transurethral resection of a bladder tumor

Contact Info

Product

Resources

About